A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.

The entities involved

• Moderna →

  American biotechnology company

  • Analyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Mon 17:09
  • Positive test results were reported for Moderna's flu vaccine.Sun 15:33
• Merck →

  public company in Indonesia

  • Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
  • Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Analyst comments on industry trends regarding Moderna's competition in the cancer vaccine market.Aug 26
• Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.Aug 28
• Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Aug 25
• Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.Aug 19
• Google gained permission to buy a $12B stake, coinciding with positive late-stage trial results for a cancer vaccine.Aug 19